Sugi Predict

Sugi Predict / Compounds / SCHEMBL1703390

SCHEMBL1703390

SCHEMBL1703390

CCCCCCCCCCCCC/C=C/C(=O)OCC(O)CO

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.68
▸ FAAH O00519 4/20 0.60
▸ KDM4E B2RXH2 1/20 0.56
▸ DUSP3 P51452 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ MAPT P10636 1/20 0.47
▸ LPAR1 Q92633 5/20 0.47
▸ ENPP2 Q13822 2/20 0.47
▸ LPAR4 Q99677 2/20 0.47
▸ LPAR5 Q9H1C0 2/20 0.47
▸ LPAR2 Q9HBW0 2/20 0.47
▸ LPAR3 Q9UBY5 2/20 0.47
▸ CES2 O00748 1/20 0.47
▸ LPAR6 P43657 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29721346 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL30733274 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL31439416 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL29542312 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL16399304 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL21772714 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL1703391 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL1427818 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL20719742 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1
SCHEMBL30570722 1.00 DGKA (0.68) DGKAFAAHKDM4EDUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360184-A1 METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES TUPIN CYRILLE (FR) 2025-11-27 — — US disclosed
US-20250352613-A1 METHODS FOR TREATING HYPERINFLAMMATORY CONDITIONS USING LIPID BINDING PROTEIN -BASED COMPLEXES FAGUER STANISLAS (FR) 2025-11-20 — — US disclosed
EP-4648788-A1 LIPID BINDING PROTEIN MOLECULE THERAPY Abionyx Pharma SA (FR) 2025-11-19 — — EP disclosed
US-20250255931-A1 METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2025-08-14 — — US disclosed
US-20250230208-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2025-07-17 — — US disclosed
WO-2025093929-A1 LIPID BINDING PROTEIN MOLECULE THERAPY ABIONYX PHARMA SA (FR) 2025-05-08 — — WO disclosed
EP-4536268-A2 METHODS FOR TREATING HYPERINFLAMMATORY CONDITIONS USING LIPID BINDING PROTEIN -BASED COMPLEXES Abionyx Pharma SA (FR) 2025-04-16 — — EP disclosed
EP-4536269-A2 METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES Abionyx Pharma SA (FR) 2025-04-16 — — EP disclosed
WO-2024150064-A9 LIPID BINDING PROTEIN MOLECULE THERAPY ABIONYX PHARMA SA (FR) 2025-02-20 — — WO disclosed
EP-4504150-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES Abionyx Pharma SA (FR) 2025-02-12 — — EP disclosed
EP-3668600-A1 CARGOMERS Abionyx Pharma SA (FR) 2020-06-24 — — EP disclosed
EP-3668549-A1 APOMERS Abionyx Pharma SA (FR) 2020-06-24 — — EP disclosed
US-20190048049-A1 CARGOMERS CERENIS THERAPEUTICS HOLDING SA (FR) 2019-02-14 — — US disclosed
WO-2019030574-A1 CARGOMERS CERENIS THERAPEUTICS HOLDING (FR) 2019-02-14 — — WO disclosed
WO-2019030575-A1 APOMERS CERENIS THERAPEUTICS HOLDING (FR) 2019-02-14 — — WO disclosed
US-20190046608-A1 APOMERS CERENIS THERAPEUTICS HOLDING SA (FR) 2019-02-14 — — US disclosed
EP-1695088-B1 METHOD FOR ANALYSING METABOLITES MAX PLANCK GESELLSCHAFT (DE) 2012-04-18 — — EP disclosed
US-20070141712-A1 Method for analysing metabolites MAX-PLANCK-GESSELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2007-06-21 — — US disclosed
EP-1695088-A1 METHOD FOR ANALYSING METABOLITES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2006-08-30 — — EP disclosed
WO-2005059556-A1 METHOD FOR ANALYSING METABOLITES MAX PLANCK GESELLLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250352613-A1 METHODS FOR TREATING HYPERINFLAMMATORY CONDITIONS USING LIPID BINDING PROTEIN -BASED COMPLEXES HDLBP, CETP, HSPBP1 DGKA 711/4885FAAH 1103/4885KDM4E 3656/4885
US-20250360184-A1 METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES FABP1, FABP3, FABP2 DGKA 753/4885FAAH 850/4885KDM4E 4599/4885
US-20250255931-A1 METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES FABP3, LIPG, HDLBP DGKA 2147/4885FAAH 2747/4885KDM4E 4007/4885
US-20250230208-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES CETP, HDLBP, APOB DGKA 2366/4885FAAH 1921/4885KDM4E 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.